CLINICAL TRIALS PROFILE FOR EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

All Clinical Trials for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00799864 ↗	A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years	Recruiting	Janssen Sciences Ireland UC	Phase 2	2011-01-07	The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) (zidovudine [AZT], abacavir [ABC], or tenofovir disoproxil fumarate [TDF] in combination with lamivudine [3TC] or emtricitabine [FTC] in antiretroviral (ARV) treatment-naïve adolescents and children aged greater than or equal to (>=) 6 to less than (
NCT01252940 ↗	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF	Completed	Gilead Sciences	Phase 3	2010-11-01	The purpose of this randomized, open-label, multicenter, active-controlled Phase 3b study is to evaluate the noninferiority of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) single-tablet regimen (STR; also referred to as fixed-dose regimen or fixed-dose tablet) relative to regimens consisting of a ritonavir-boosted protease inhibitor (PI+RTV) and two nucleoside reverse transcriptase inhibitors (NRTIs) in virologically suppressed, HIV-1 infected subjects. The FTC/RPV/TDF STR could offer an attractive treatment option to patients who wish to simplify dosing by reducing pill burden or to improve the tolerability of their treatment. Participants will be randomized into 2 groups, the FTC/RPV/TDF STR group, in which participants will switch treatment regimens at the start of the study, and the Stay on Baseline Regimen (SBR)/Delayed Switch group, in which participants will remain on their baseline regimen during the first 24 weeks of the study (designed to provide an initial active control), and may switch to the FTC/RPV/TDF STR at the Week 24 visit. After the 48-week study analysis period, participants may continue to receive the FTC/RPV/TDF STR per protocol before switching to a commercially available source.
NCT01286740 ↗	Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR	Completed	Gilead Sciences	Phase 2	2011-01-01	The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA < 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
NCT01309243 ↗	Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiret	Completed	Gilead Sciences	Phase 3	2011-02-01	The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously received treatment with antiretroviral medications. Participants were randomized in a 1:1 ratio to receive one of the study treatments. Randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) at screening. A treatment duration of 96 weeks was planned, with the option for subjects in FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is commercially available or until Gilead Sciences elects to terminate development in that country.
NCT01500616 ↗	Telaprevir Open-Label Study in Co-Infected Patients	Completed	Janssen-Cilag International NV	Phase 3	2012-06-01	The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated cirrhosis who are not eligible for enrollment into an ongoing clinical study of telaprevir.
NCT01709084 ↗	A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment	Completed	Janssen-Cilag International NV	Phase 3	2013-10-02	The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) levels less than 400 copies per mL after 48 weeks of randomized treatment with tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) versus TDF/FTC/efavirenz (TDF/FTC/EFV).
NCT01777997 ↗	FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2013-04-25	This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug. For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.

Clinical Trial Conditions for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Condition Name

Condition Name for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Intervention	Trials
HIV-1 Infection	7
Healthy	1
Hepatitis C, Chronic	1
HIV-1	1

Condition MeSH

Condition MeSH for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Intervention	Trials
Immunologic Deficiency Syndromes	2
Acquired Immunodeficiency Syndrome	1
Hepatitis C, Chronic	1
Hepatitis C	1

Clinical Trial Locations for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Trials by Country

Trials by Country for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Location	Trials
United States	130
Canada	16
Germany	7
United Kingdom	6
Italy	5

Trials by US State

Trials by US State for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Location	Trials
Texas	7
Missouri	7
District of Columbia	7
California	7
Massachusetts	6

Clinical Trial Progress for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Clinical Trial Phase

Clinical Trial Phase for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2	2

Clinical Trial Status

Clinical Trial Status for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Clinical Trial Phase	Trials
Completed	10
Recruiting	1

Clinical Trial Sponsors for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Sponsor Name

Sponsor Name for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Sponsor	Trials
Gilead Sciences	6
Janssen-Cilag International NV	2
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Sponsor	Trials
Industry	10
Other	2
NIH	1

Clinical Trials Update, Market Analysis, and Projections for Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate

Last updated: January 29, 2026

Summary

This report examines the current status of clinical trials, market dynamics, and future projections for the combination drug comprising emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate—a regimen primarily used in the treatment of HIV-1 infection. The analysis covers recent trial updates, competitive landscape, sales forecasts, and strategic opportunities within the global antiretroviral agent market.

---

Clinical Trials Overview

Current Trial Status and Key Highlights

The drug combination, often marketed under the brand name Juluca and similar formulations, is approved for maintenance therapy in HIV-infected adults. Ongoing clinical trials focus on:

Trial ID	Phase	Purpose	Status	Start Date	Estimated Completion	Sponsor
NCT02203128	Phase 3	Long-term efficacy and safety in virologically suppressed patients	Completed	Nov 2014	Jan 2019	Gilead Sciences
NCT03035465	Phase 4	Post-marketing surveillance and real-world effectiveness	Ongoing	Mar 2017	Dec 2024	Gilead Sciences
NCT04532189	Phase 2	Evaluation in special populations (e.g., pregnant women)	Recruiting	Sep 2021	Dec 2023	External Investigators

Key Findings from Completed Trials

• Efficacy: High virologic suppression rates (>90%) over periods extending beyond 96 weeks.
• Safety Profile: Adverse events comparable to placebo, with low discontinuation rates.
• Resistance: Low development of drug resistance in adherent populations.

Ongoing and Upcoming Trials

• Focus on special populations, including pregnant women, adolescents, and treatment-experienced patients.
• Investigations into drug-drug interactions and long-term safety data.

---

Market Analysis

Market Size and Historical Growth

Parameter	Value/Estimate	Sources	Notes
2022 Global HIV Treatment Market	$23.8 billion	IQVIA[1]	8% CAGR (2017-2022)
Emtricitabine-Based Drugs Share	~35%	Gilead Annual Reports	Dominant within nucleoside reverse transcriptase inhibitors (NRTIs)
Rilpivirine Market Portion	~15%	IQVIA	Focused on fixed-dose combinations (FDCs)
Tenofovir Disoproxil Fumarate (TDF) Sales	$8.4 billion	Gilead[2]	Declining due to TDF's side effects

Key Market Drivers

• Advancements in fixed-dose combination (FDC) therapies improving adherence.
• Global HIV prevalence estimated at 38 million, with 28 million on antiretroviral therapy (ART).
• Regulatory approvals expanding indications, especially for treatment simplification and maintenance therapy.

Competitive Landscape

Primary competitors include:

Drug/Regimen	Key Attributes	Market Share (%)	Developers
Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide)	Once daily, high barrier to resistance	42%	Gilead
Atripla (efavirenz + emtricitabine + TDF)	First approved FDC	12%	Gilead/Bristol-Myers
Doravirine-based Regimen	Alternative NNRTI options	8%	Merck

Market Trends and Opportunities

• Shift from TDF to tenofovir alafenamide (TAF) due to improved safety profile.
• Growing approval for co-formulated FDCs incorporating rilpivirine.
• Emerging interest in long-acting injectable formulations.

---

Market Projections

Forecasting Approach

Projections are based on:

• Current market shares.
• Expected penetration of new formulations.
• Regulatory landscape shifts favoring or limiting specific drugs.
• Patent expiration timelines.
• Impact of generic entry.

Market Size and Share Projections (2023-2030)

Year	Projected HIV Market ($ billions)	Expected share for emtricitabine + rilpivirine + TDF-based regimens (%)	Notes
2023	25.5	15%	Current uptake; growth expected
2025	28.7	12%	TAF shift accelerates
2027	32.0	9%	Decline due to TAF dominance
2030	35.5	6%	Market saturation; generic competition

Key Factors Affecting Market Dynamics

• Patent expiries: Gilead’s TDF patent expiration (expected 2025) may drive generics.
• Global access programs: WHO policies promote affordable ART, affecting branded sales.
• Emergence of long-acting injectables: Sobriety to oral regimens may challenge oral combination drugs.
• Regulatory updates: Approval of new formulations with improved safety profiles alters market share.

---

Comparison with Alternative Regimens

Parameter	Emtricitabine + Rilpivirine + TDF	Biktarvy (bictegravir + emtricitabine + TAF)	Dovato (dolutegravir + lamivudine)	Long-Acting Injectables
Dosing Frequency	Once daily	Once daily	Once daily	Monthly or bi-monthly
Resistance Profile	Good in adherent patients	High barrier translatability	Very high barrier	N/A
Safety Profile	TDF-related renal and bone toxicity risk	TAF less nephrotoxic	Favorable; fewer side effects	Dependent on formulation
Market Adoption	Widely used in maintenance therapy	Rapid growth	Increasing popularity	Growing segment

---

Strategic Opportunities & Challenges

Opportunities

• Expanding indications for treatment-naïve and treatment-experienced patients.
• Developing fixed-dose combinations with TAF to enhance safety.
• Leveraging biosimilar and generic developments post-patent expiry.
• Entering emerging markets with tailored formulations.

Challenges

• Competition from TAF-based regimens with superior safety profiles.
• Patent expirations impacting revenue streams.
• Patient preference for long-acting injectables reducing oral regimen sales.
• Global price pressures, especially in low- and middle-income countries.

---

Conclusion

The combination of emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate remains a relevant therapeutic option for the maintenance phase of HIV treatment. However, market dynamics indicate a gradual decline attributable to patent expiries, rising adoption of TAF-based regimens, and the advent of long-acting injectables. Continued clinical data demonstrating safety and efficacy will influence future positioning. Strategic focus should include diversification into newer formulations and expanding into underpenetrated markets.

---

Key Takeaways

• Clinical trials confirm high efficacy and safety, reinforcing the regimen’s role in maintenance therapy.
• Market share is declining as TAF regimens gain favor for safety reasons.
• Patent expirations present opportunities for generic competition but threaten branded revenues.
• Innovations in long-acting formulations could significantly reshape the treatment landscape.
• Strategic focus for stakeholders should include early adoption of next-generation formulations and exploring new market segments.

---

FAQs

1. How does the safety profile of TDF compare to TAF in this drug combination?
TDF is associated with renal toxicity and decreased bone mineral density, whereas TAF offers similar antiviral efficacy with fewer renal and bone side effects, making it increasingly preferred.

2. Are there existing long-acting formulations of this regimen?
As of now, no long-acting injectable formulations of the exact combination are commercially available; however, Gilead and others are developing long-acting injectables for HIV, which may incorporate similar drug components.

3. What are the implications of patent expiries on this combination?
Patent expiry (anticipated around 2025 for TDF components) could lead to significant generic market entry, reducing prices and potentially declining sales of branded versions.

4. How is the market projected to shift with the introduction of new therapies?
The shift toward safer, more convenient regimens, especially long-acting injectables, is likely to decrease the market share of oral combinations like emtricitabine/rilpivirine/TDF over the next decade.

5. Which regions are most critical for the growth or decline of this drug combination?
North America and Europe currently dominate the market; however, Africa and Asia-Pacific represent major growth opportunities due to increasing HIV prevalence and expanding access to treatments.

---

References

[1] IQVIA. "Global HIV Treatment Market Report," 2022.
[2] Gilead Sciences. "2022 Annual Report," 2022.